114 related articles for article (PubMed ID: 27027032)
1. IS THERE ANY DIFFERENCE IN THE PROGNOSIS FOR PATIENTS WITH PRIMARY OSTEOSARCOMA WITH A POOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY BETWEEN HUVOS GRADES I AND II?
Bispo Júnior RZ; Camargo OP
Rev Bras Ortop; 2011; 46(4):420-3. PubMed ID: 27027032
[TBL] [Abstract][Full Text] [Related]
2. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
Xu J; Xie L; Guo W
Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center.
Vijayanarasimha D; Nayanar SK; Vikram S; Patil VM; Babu S; Satheesan B
Indian J Surg Oncol; 2017 Jun; 8(2):136-141. PubMed ID: 28546707
[TBL] [Abstract][Full Text] [Related]
5. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jung ST; Jeon DG
J Orthop Sci; 2009 May; 14(3):292-7. PubMed ID: 19499296
[TBL] [Abstract][Full Text] [Related]
6. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
7. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution.
Bacci G; Mercuri M; Longhi A; Ferrari S; Bertoni F; Versari M; Picci P
Eur J Cancer; 2005 Sep; 41(14):2079-85. PubMed ID: 16115755
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
Yang YK; Xu HR; Huang Z; Li Y; Niu XH
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):692-696. PubMed ID: 32867464
[No Abstract] [Full Text] [Related]
10. Morphological aspects of the hepatic response to neoadjuvant therapy.
Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
[TBL] [Abstract][Full Text] [Related]
11. [Osteosarcoma lung metastases. Survival after chemotherapy and surgery].
Farfalli GL; Albergo JI; Lobos PA; Smith DE; Streitenberger PD; Pallotta Rodríguez MG; Aponte-Tinao LA
Medicina (B Aires); 2015; 75(2):87-90. PubMed ID: 25919869
[TBL] [Abstract][Full Text] [Related]
12. [The prognostic factors in astrocytic tumors: analysis by the Kaplan-Meier method and the Weibull log-linear model].
Hirano H; Asakura T; Yokoyama S; Kadota K; Kasamo S; Okahara K; Hirakawa W; Niiro M; Nakamura K; Nakayama M; Yamasaki I
No Shinkei Geka; 1996 Sep; 24(9):809-15. PubMed ID: 8827730
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma of the spine: experience in 26 patients treated at the Massachusetts General Hospital.
Schoenfeld AJ; Hornicek FJ; Pedlow FX; Kobayashi W; Garcia RT; DeLaney TF; Springfield D; Mankin HJ; Schwab JH
Spine J; 2010 Aug; 10(8):708-14. PubMed ID: 20650409
[TBL] [Abstract][Full Text] [Related]
14. Telangiectatic osteosarcoma: a review of 87 cases.
Angelini A; Mavrogenis AF; Trovarelli G; Ferrari S; Picci P; Ruggieri P
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2197-207. PubMed ID: 27469493
[TBL] [Abstract][Full Text] [Related]
15. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
16. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis.
Nathan SS; Gorlick R; Bukata S; Chou A; Morris CD; Boland PJ; Huvos AG; Meyers PA; Healey JH
Cancer; 2006 Oct; 107(7):1607-16. PubMed ID: 16933325
[TBL] [Abstract][Full Text] [Related]
17. Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.
Crenn V; Biteau K; Amiaud J; Dumars C; Guiho R; Vidal L; Nail LL; Heymann D; Moreau A; Gouin F; Redini F
Am J Cancer Res; 2017; 7(11):2333-2349. PubMed ID: 29218254
[TBL] [Abstract][Full Text] [Related]
18. Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
Kimura H; Tsuchiya H; Shirai T; Nishida H; Hayashi K; Takeuchi A; Ohnari I; Tomita K
J Orthop Sci; 2009 Sep; 14(5):556-65. PubMed ID: 19802667
[TBL] [Abstract][Full Text] [Related]
19. VEGF expression as a prognostic marker in osteosarcoma.
Bajpai J; Sharma M; Sreenivas V; Kumar R; Gamnagatti S; Khan SA; Rastogi S; Malhotra A; Bakhshi S
Pediatr Blood Cancer; 2009 Dec; 53(6):1035-9. PubMed ID: 19621435
[TBL] [Abstract][Full Text] [Related]
20. A new relative tumor sizing method in epi-metaphyseal osteosarcoma.
Kim SH; Shin KH; Park EH; Cho YJ; Park BK; Suh JS; Yang WI
BMC Cancer; 2015 Apr; 15():284. PubMed ID: 25885468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
